ResearcherThe University of Texas Rio Grande ValleyActive in the last 2 years
Anupam Dhasmana
Matched on ORCID iD 0000-0002-8042-940X; OpenAlex author ID A5037562966. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper
Papers 7
- MUC13-Associated Molecular Interactome in Pancreatic Cancer. Co-author DOI 10.34133/csbj.0056↗
- Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102432↗
- Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1543112↗
- Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1662270↗
- CEACAM7 expression contributes to early events of pancreatic cancer. Co-author DOI 10.1016/j.jare.2023.02.013↗
- Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.04.029↗
- An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. First author DOI 10.1016/j.csbj.2023.11.029↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Murali Mohan Yallapu · 7 shared papers, 2023–2026 · strength 1.65
- Paper MUC13-Associated Molecular Interactome in Pancreatic Cancer. DOI 10.34133/csbj.0056↗
- Paper Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic … DOI 10.1016/j.tranon.2025.102432↗
- Paper Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1543112↗
- Subhash C. Chauhan · 7 shared papers, 2023–2026 · strength 1.65
- Paper MUC13-Associated Molecular Interactome in Pancreatic Cancer. DOI 10.34133/csbj.0056↗
- Paper Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic … DOI 10.1016/j.tranon.2025.102432↗
- Paper Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1543112↗
- Swati Dhasmana · 6 shared papers, 2023–2026 · strength 1.38
- Paper MUC13-Associated Molecular Interactome in Pancreatic Cancer. DOI 10.34133/csbj.0056↗
- Paper Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1543112↗
- Paper Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1662270↗
- Sheema Khan · 5 shared papers, 2023–2025 · strength 1.06
- Paper Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1543112↗
- Paper Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. DOI 10.3389/fphar.2025.1662270↗
- Paper CEACAM7 expression contributes to early events of pancreatic cancer. DOI 10.1016/j.jare.2023.02.013↗
- Shafiul Haque · 4 shared papers, 2023–2026 · strength 0.90
- Paper MUC13-Associated Molecular Interactome in Pancreatic Cancer. DOI 10.34133/csbj.0056↗
- Paper CEACAM7 expression contributes to early events of pancreatic cancer. DOI 10.1016/j.jare.2023.02.013↗
- Paper Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.04.029↗
- Shabia Shabir · 2 shared papers, 2025 · strength 0.47
- Stephen W. Behrman · 2 shared papers, 2025 · strength 0.47
- Russell Moreland · 2 shared papers, 2025 · strength 0.47
- Meena Jaggi · 2 shared papers, 2023–2024 · strength 0.41
- Bilal Bin Hafeez · 1 shared paper, 2025 · strength 0.27
- Mudassier Ahmad · 1 shared paper, 2025 · strength 0.27
- Upender Manne · 1 shared paper, 2023 · strength 0.18
- Farrukh Afaq · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.